Oxford Biomedica to host webinar showcasing the TetraVecta™ system
Oxford Biomedica to host webinar showcasing the TetraVectaTM system
Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVectaTM system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023.
The webinar titled “4th Generation Lentiviral Vectors: An Improved Gene Delivery System” will feature presentations by Dr Nick Clarkson, Vice President, Head of Platform Research at Oxford Biomedica and Dr Dan Farley, Senior Director of the Vector Engineering Group at Oxford Biomedica, who will discuss how the TetraVecta™ system can significantly enhance the development and manufacturing of safer and more effective lentiviral vector-based therapies through improved quality, potency and packaging capacity. The presentation will also explore how these new vectors have the potential to streamline complex manufacturing processes, enhance productivity and open possibilities for developing new treatments.
The webinar will be held at 16:00 BST / 11:00 EST on Monday 2 October 2023, followed by a live Q&A session. To register for the webinar, please click .
Oxford Biomedica’s TetraVectaTM system launched in following years of development and on the basis of detailed understanding of specific industry challenges. This cutting-edge technology paves the way for genuine plug and play manufacturing and is being rolled out to support the development of more complex advanced therapies.
-Ends-
Enquiries:
Oxford Biomedica plc:
Sebastien Ribault, Chief Commercial Officer – T: +44 (0)7519 109325 / E:
Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 7394 562 425 / E:
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E:
Mary-Jane Elliott / Matthew Neal / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at , , and follow us on and .
